HomeCONGRESS

CONGRESS

View Category
Day 3

Resynchronization therapy is not beneficial in patients with heart failure and narrow QRS

Resynchronization therapy has shown benefits reducing morbidity and mortality in patients with heart failure and wide QRS....
solaci -
Learn More
Day 3

AQUARIUS: Aliskiren, without impact on the progression of atherosclerosis

This double-blind, multicenter randomized study compared aliskiren versus placebo in 613 patients with coronary artery disease and...
solaci -
Learn More
Day 3

BIC 8: Copetin associated with troponin can rule out acute myocardial infarction in the emergency room.

The acute chest pain is responsible for more than 11 % of queries to an emergency service...
solaci -
Learn More
Day 3

Group Tour of France: good news for cyclists.

The benefits of regular physical activity are well established, but there are some controversies related to the...
solaci -
Learn More
Day 2

SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit

The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4...
solaci -
Learn More
Day 2

ASSURE: Inducing Apo A-1 agent failed to reduce atherosclerotic plaque

Induction apoA-1  synthesis is a new therapeutic approach for the functional HDL particles generation. The RVX-208 induces...
solaci -
Learn More
Day 2

COMPARE: Losartan shows promising results in patients with Marfan syndrome

Patients with Marfan syndrome (connective tissue disorder) are more susceptible to aortic dilation and consequently dissection and...
solaci -
Learn More
Day 2

EXAMINE: The alogliptin is safe for treating type 2 diabetes in patients with a recent history of acute coronary syndrome.

Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk...
solaci -
Learn More